Despite barriers of blood, brain and bureaucracy, intranasal insulin may emerge as a promising treatment for pathological memory loss
The newest chemical under investigation for managing Alzheimer’s disease (AD) is actually not new at all. Insulin, the therapeutic hormone all-too familiar to individuals with diabetes, has been around for decades. In fact December will mark 90 years since its discoverers earned the Nobel Prize in Physiology or Medicine for the extraction of insulin for clinical use. Yet to say that insulin has been under our noses all these years wouldn’t exactly be correct. Because if it had been under our noses, we might have sensed its neurologic benefits sooner.
The latest insulin therapy is not delivered via injection like its diabetes-treating counterparts, nor does it come in the form of a pill or a patch like the cholinesterase inhibitors often prescribed to patients with AD. Instead this novel therapeutic enters the body through the nose—the only entry point that gives insulin a chance of reaching the brain.
A large peptide molecule, insulin from the blood cannot float easily into the brain because the blood brain barrier (BBB), a sort of neuroprotective moat, prevents its transport. Fortified by cellular guards called tight junctions, the BBB rejects many pharmacologic hopefuls, allowing entrance only to certain types of substances. Namely small or lipophilic molecules can be administered orally (or via injection, or through the skin) and as long as the relevant chemicals end up in the blood stream, they can casually saunter across the BBB and act on the brain. Large and cumbersome, insulin does not have this luxury and must therefore take a more creative route across the moat.
The nose, conspicuous and sometimes even goofy, provides that creative route. Yet it’s a route that, for many years, researchers were hesitant to take.
“They would say things like, ‘Well, why would there be a blood brain barrier if all you had to do was put something in the nose and it would go to the brain?’” says William H. Frey II, Ph.D., Research Director at HealthPartners Center for Memory & Aging. As of 1989 Frey had been “in the Alzheimer’s deal” for over a decade. At that time he was conducting clinical trials of a neurotrophic factor (a therapeutic protein) to treat AD and, because of the seeming insurmountability of the BBB, the work had been less than fruitful. “It became clear to me that, once again, this neurotrophic factor was not getting effectively into the brain,” he says. So Frey decided to sleep on it. “I went to sleep and I had a dream. And this is how I discovered the intranasal method of getting around the blood brain barrier,” he says. “It had been known since the early 1900s that a number of different viruses that got into the nose would travel up the olfactory nerves and the trigeminal nerves—both of these are nerves that go directly from the nasal mucosa right into the brain. The idea that came to me in this dream in 1989 was: if bad things can do it, why can’t good things do it?”
When Frey revisited the idea upon waking, it registered as simultaneously intuitive and absurd—a logical fantasy like so many dreams.
The Latest Bing News on:
- Tonix deal sets up use of intranasal drug in diabetes, obesityon January 5, 2021 at 8:15 am
Researchers linked the changes to improvements in lipid metabolism, glucose intolerance and insulin resistance. Subsequent research has tied intranasal oxytocin to positive effects on weight ...
- New Diabetes Technology: What to Expect in 2021on January 3, 2021 at 4:01 pm
For example, non-insulin using type 2s or general health ... following the Baqsimi nasal glucagon from Eli Lilly and the Gvoke rescue pen and prefilled syringe by Xeris Pharmaceuticals.
- Intranasal Insulin Enhanced Resting-state Functional Connectivity of Hippocampal Regions in Type 2 Diabeteson January 1, 2021 at 4:00 pm
Type 2 diabetes mellitus (T2DM) alters brain function and manifests as brain atrophy. Intranasal insulin has emerged as a promising intervention for treatment of cognitive impairment. We evaluated ...
- Covid 'long-haul' symptoms leave survivors in emotional limbo. It's a familiar pain.on December 30, 2020 at 6:47 am
But I received a double-armed IV flush of insulin and fluids ... Unfortunately, according to the nasal swab I got later that day, I did not, in fact, have the coronavirus. A week later, I was ...
- FDA Nod For First Generic Drug To Treat Severe Hypoglycemiaon December 29, 2020 at 6:08 am
While insulin lowers blood sugar levels by moving ... In July 2019, the FDA gave nod to the glucagon nasal powder Baqsimi from Eli Lilly to treat severe hypoglycaemia, which is normally treated ...
- Price controls, currency devaluation fuel drug shortages in Egypton December 25, 2020 at 4:00 pm
Products that have suffered recent shortages range from government-subsidized imported baby formula and insulin, to locally produced nasal drops and laxatives and hormonal drugs used to treat ...
- Early Intranasal Insulin Therapy Halts Progression of Neurodegenerationon December 25, 2020 at 4:00 pm
 The subjects were treated with either a placebo, or one of two doses (20–40 IU) of intranasal insulin. At the end of a 4-month protocol, memory and cognitive performance were assessed to ...
- Automated Insulin Delivery System Market Research Report by Disease Type, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19on December 24, 2020 at 4:07 pm
(MENAFN - GlobeNewsWire - Nasdaq) New York, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Automated Insulin Delivery System Market Research Report by ...
- Human Insulin Market to Grow to be Valued USD 43.33 Billion by 2025 – TechSci Researchon December 23, 2020 at 1:14 am
“Global Human Insulin Market By Indication (Type I Diabetes ... Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus ...
- University of Geneva Technology Covers Broad Applications for Cardiometabolic Syndromeson December 22, 2020 at 7:23 am
“Subsequent to the University of Geneva inventions, a number of studies have shown that intranasal oxytocin has effects on insulin resistance and weight2-4,” continued Dr. Lederman.
The Latest Google Headlines on:
The Latest Bing News on:
- I’m predisposed to early-onset Alzheimer’s. I want to propose to my girlfriend — but unsure how to divide my estate between her and my daughteron January 20, 2021 at 10:26 am
Is it wrong to leave funds passed down from generation to generation solely for my daughter, and leave other funds to my new wife?’ ...
- Eli Lilly Stock Is Surging on Hope for Alzheimer’s Drug. Analyst Says It Won’t Last.on January 20, 2021 at 7:49 am
The company has said it will provide detailed data on the treatment on March 13. The stock is up some 19% over the past week.
- Alzheimer’s Disease Therapeutics and Diagnostics Market Share Current and Future Industry Trends, 2020-2025on January 20, 2021 at 7:29 am
The research report on Alzheimer’s Disease Therapeutics and Diagnostics market provides with a granular evaluation of the business space and contains information regarding the market tendencies such ...
- Startup Scene: Firm aims to detect Alzheimer's earlieron January 20, 2021 at 7:16 am
San Francisco-based mental health startup Coa has been cited as a firm to watch as mental health companies become more vital in the pandemic. Initial growth has come virtually but Coa has concrete ...
- Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical ...on January 20, 2021 at 3:10 am
(GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel pharmacotherapy: NNI-362 to allosterically ...
- Five Habits That Can Decrease Chances of Alzheimer's, Even For Those With Genetic Riskon January 19, 2021 at 10:23 pm
Those who have a parent, a sibling, or multiple family ties with Alzheimer's are more likely to develop the disease than those who do not have a first-degree relative with Alzheimer's. Fortunately, ...
- ACRS Soars On RA Trial Data, BHVN Disappoints In Alzheimer's Trial, GRTS Joins COVID-19 Vaccine Raceon January 19, 2021 at 9:38 pm
Today's Daily Dose brings you news about another Alzheimer's disease drug failure, encouraging data of Aclaris' rheumatoid arthritis trial; Royalty Pharma/Minerva deal; Gritstone joining the COVID-19 ...
- Clare Crawley’s Ex-Fiance Benoit Beausejour-Savard Sends Support Amid Mom’s Alzheimer’s Battle, Dale Spliton January 19, 2021 at 3:37 pm
Bachelorette’ alum Clare Crawley got support from her ex-fiance Benoit Beausejour-Savard amid her mom’s Alzheimer’s journey and Dale Moss breakup — details ...
- Summerville's Alzheimer's support nonprofit celebrates 25 years of serviceon January 19, 2021 at 11:55 am
Peg Lahmeyer and other members of St. Luke’s Lutheran Church in Summerville started a ministry dedicated to supporting people with Alzheimer's and the caregivers who look after them.
- Visual arts: Painter responds to mother's battle with Alzheimer's disease with arton January 19, 2021 at 1:10 am
Susanne Dotson's show at Sarah Gormley Gallery in the Short North was inspired by her mother, who died Dec. 20.